BARRI

Baricitinib is a Janus kinase (JAK) inhibitor indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

TNF antagonist

Baricitinib is a selective and reversible inhibitor of Janus kinase JAK1 and JAK2. Janus kinases (JAKs) are enzymes that transduce intracellular signals from cell surface receptors for a number of cytokines and growth factors involved in haematopoiesis, inflammation and immune function. Within the intracellular signalling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), which activate gene expression within the cell. Baricitinib modulate these signalling pathways by partially inhibiting JAK1 and JAK2 enzymatic activity, thereby reducing the phosphorylation and activation of STATs.

The recommended dose of Baricitinib is 2 mg once daily. It may be used as monotherapy or in combination with methotrexate or other DMARDs.

Baricitinib is not recommended in patients taking strong Organic Anion Transporter 3 (OAT3) inhibitors (e.g., probenecid).

Serious Infections: Avoid use of Baricitinib in patients with active, serious infection, including localized infections. If a serious infection develops, interrupt Baricitinib therapy until the infection is controlled. Do not give Baricitinib to patients with active tuberculosis. Thrombosis: Use with caution in patients who may be at increased risk. Gastrointestinal Perforations: Use with caution in patients who may be at increased risk. Laboratory Assessment: Recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes, and lipids. Vaccinations: Avoid use of Baricitinib with live vaccines. 

upper respiratory tract infections, nausea, herpes simplex, and herpes zoster.

Data in pregnant women are insufficient to inform pregnancy category.

In case of an overdose, it is recommended that the patient should be monitored for signs and symptoms of adverse reactions. Patients who develop adverse reactions should receive appropriate treatment.

Store at or below 30°C temperature. Keep away from light and wet place. Keep out of reach of children.

No specific Data available